Kowa Company Limited

The University of Tokyo

Juridical Foundation the Chemo-sero-therapeutic Research Institute

Perseus Proteomics Inc.

The Chemo-sero-therapeutic Research Institute

Masao Ohkuchi

Yoshinori Kyotani

Tomoyuki Koshi

Tatsuhiko Kodama

Takeshi Doi

Masahiro Tamura

Yukiyoshi Yamazaki

Toshiaki Oda

Takayuki Matsuda

Hiromichi Shigyo

Masahiro Nishikawa

Shunji Takemura

Takahiro Kitamura

Hideo Yoshizaki

Kyoko Kotaki

Natsuyo Kumai

Tadaaki Ohgiya

Toshihiro Nakashima

Akio Iwasaki

Takao Hamakubo

Toshiyuki Edano

Hiroko Iwanari

Shigeru Kimura

Tsukasa Nishihara

Yushi Saino

Kyoko Yasuoka

Takumi Sasaki

Yasuomi Urano

Taisuke Tomita

Ikuo Hayashi

Atsuko Sakata

Yuriko Habata

Takeshi Iwatsubo

Seiichi Sato

Soichi Oda

Kazuhiko Kimachi

Toshimi Mizoguchi

Junko Totsuka

Sumiyo Takemoto

Shigeki Kuwata

Tomoko Furuyama

Tsukasa c/o Juridical Foundation Nishihara

Shigeki c/o Juridical Foundation Kuwata

Kazuhiko c/o Juridical Foundation Kimachi

Toshihiro c/o Juridical Foundation Nakashima

Takumi c/o Juridical Foundation Sasaki

Takumi c/o Juridical Foundation The Sasaki

Toshihiro c/o Juridical Foundation The Nakashima

Sumiyo c/o Juridical Foundation The Takemoto

Tsukasa c/o Juridical Foundation The Nishihara

Tatsuhiko c/o The University Of Tokyo Kodama

Yasuomi Department Of Biotechemistry Dartmouth Medical School Urano

Taisuke c/o The University Of Tokyo Tomita

Takao c/o The University Of Tokyo Hamakubo

Takeshi c/o The University Of Tokyo Iwatsubo

To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.

Therapeutic agents for alzheimer's disease and cancer

A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.

Modified SEB and prophylactics/remedies for immunopathy containing the same

A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.

Protease-resistant modified SEB and vaccine containing the same

The present invention is directed to a compound represented by formula (1): (wherein Rrepresents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of Rand Rrepresents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or Rand Rform, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-&#x3b1;) production inhibitory effect and improved absorption upon oral administration.

Benzofuran derivative

A cyclic amine compound represented by the following general formula (1):wherein, These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Cyclic amine compounds and pharmaceutical composition containing the same

Pyridazin-3-one derivatives and medicines containing the same

Phenylpyridazine compounds and medicines containing the same

Pyridazine derivatives and drugs containing the same as the active ingredient

Pyridazine compounds and compositions containing the same

Thrombin-binding substances capable of promoting anti-thrombin III activity and inhibiting platelet aggregation, and by themselves possessing anti-thrombin activity are disclosed. The thrombin-binding substances are useful as an effective component of anticoagulant agents, and can be produced inexpensively on a large scale.

DNA encoding a human thrombomodulin having a modified glycosaminoglycan

Recombinant thrombin-binding substances, derived from thrombomodulin by modification of the c-terminal glycosaminoglycan (GAG) binding site and capable of promoting anti-thrombin III activity and inhibiting platelet aggregation, and by themselves possessing anti-thrombin activity are disclosed. The thrombin-binding substances are useful as an effective component of anticoagulant agents, and can be produced inexpensively in a large scale.

Human urinary thrombomodulin with a modified glycosaminoglycan (GAG)

Growing community of inventors

Tokorozawa, Japan

Masao Ohkuchi